Search

Noble E. Jarrell

Examiner (ID: 14167, Phone: (571)272-9077 , Office: P/1625 )

Most Active Art Unit
1699
Art Unit(s)
1625, 1699, 1622, 1624, 1609
Total Applications
1419
Issued Applications
950
Pending Applications
180
Abandoned Applications
334

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 19402269 [patent_doc_number] => 20240285780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => PEPTIDE EXHIBITING BOTULINUM TOXIN-LIKE ACTIVITY, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/009388 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5870 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009388 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/009388
PEPTIDE EXHIBITING BOTULINUM TOXIN-LIKE ACTIVITY, AND USE THEREOF Jun 10, 2021 Pending
Array ( [id] => 18597138 [patent_doc_number] => 20230271930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => PROCESS FOR ISOLATION AND PURIFICATION OF THCA FROM CANNABIS [patent_app_type] => utility [patent_app_number] => 18/009029 [patent_app_country] => US [patent_app_date] => 2021-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009029 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/009029
PROCESS FOR ISOLATION AND PURIFICATION OF THCA FROM CANNABIS Jun 7, 2021 Pending
Array ( [id] => 18530258 [patent_doc_number] => 20230235328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => NOVEL MORPHOLINO OLIGONUCLEOTIDE DERIVATIVES [patent_app_type] => utility [patent_app_number] => 18/007830 [patent_app_country] => US [patent_app_date] => 2021-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10660 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18007830 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/007830
NOVEL MORPHOLINO OLIGONUCLEOTIDE DERIVATIVES Jun 6, 2021 Pending
Array ( [id] => 17126104 [patent_doc_number] => 20210300872 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => SECOND GENERATION GRP94-SELECTIVE INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/341047 [patent_app_country] => US [patent_app_date] => 2021-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21273 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17341047 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/341047
Second generation GRP94-selective inhibitors Jun 6, 2021 Issued
Array ( [id] => 19681546 [patent_doc_number] => 20250000091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => GRAFTABLE BIOCIDAL LINKERS AND POLYMERS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/000777 [patent_app_country] => US [patent_app_date] => 2021-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36925 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000777 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/000777
GRAFTABLE BIOCIDAL LINKERS AND POLYMERS AND USES THEREOF Jun 4, 2021 Pending
Array ( [id] => 18468741 [patent_doc_number] => 20230203023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => SALT AND CRYSTAL FORMS OF GLP-1R AGONISTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/927502 [patent_app_country] => US [patent_app_date] => 2021-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927502 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/927502
SALT AND CRYSTAL FORMS OF GLP-1R AGONISTS AND USES THEREOF May 25, 2021 Pending
Array ( [id] => 19904084 [patent_doc_number] => 12281080 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-22 [patent_title] => Quinoline-based compounds and methods of inhibiting CDK8/19 [patent_app_type] => utility [patent_app_number] => 17/330279 [patent_app_country] => US [patent_app_date] => 2021-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 33 [patent_no_of_words] => 16561 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17330279 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/330279
Quinoline-based compounds and methods of inhibiting CDK8/19 May 24, 2021 Issued
Array ( [id] => 18435921 [patent_doc_number] => 20230183215 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => Notch Inhibitors and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/925916 [patent_app_country] => US [patent_app_date] => 2021-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 92326 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -79 [patent_words_short_claim] => 612 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17925916 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/925916
Notch Inhibitors and Uses Thereof May 20, 2021 Pending
Array ( [id] => 20453020 [patent_doc_number] => 12516070 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-06 [patent_title] => Fused ring derivatives and use thereof in pharmacy [patent_app_type] => utility [patent_app_number] => 17/926285 [patent_app_country] => US [patent_app_date] => 2021-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 21296 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926285 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/926285
Fused ring derivatives and use thereof in pharmacy May 17, 2021 Issued
Array ( [id] => 18877404 [patent_doc_number] => 20240000773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF SEPSIS AND SYMPTOMS THEREOF [patent_app_type] => utility [patent_app_number] => 17/925798 [patent_app_country] => US [patent_app_date] => 2021-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12028 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17925798 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/925798
Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof May 16, 2021 Issued
Array ( [id] => 18420060 [patent_doc_number] => 20230174521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/924780 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17924780 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/924780
NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS May 12, 2021 Pending
Array ( [id] => 17988922 [patent_doc_number] => 20220354959 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF [patent_app_type] => utility [patent_app_number] => 17/318723 [patent_app_country] => US [patent_app_date] => 2021-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 96071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17318723 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/318723
GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF May 11, 2021 Abandoned
Array ( [id] => 18511343 [patent_doc_number] => 20230227485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => METAL IRIDIUM COMPLEX AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/928908 [patent_app_country] => US [patent_app_date] => 2021-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9691 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 280 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928908 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/928908
METAL IRIDIUM COMPLEX AND USE THEREOF May 8, 2021 Pending
Array ( [id] => 20057279 [patent_doc_number] => 20250195501 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-19 [patent_title] => CELL ENTRY-MODULATING AGENTS AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 17/998099 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24671 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998099 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/998099
CELL ENTRY-MODULATING AGENTS AND USES THEREFOR May 6, 2021 Pending
Array ( [id] => 18449651 [patent_doc_number] => 20230190927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 17/923421 [patent_app_country] => US [patent_app_date] => 2021-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35190 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923421 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/923421
ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE May 3, 2021 Pending
Array ( [id] => 18420023 [patent_doc_number] => 20230174484 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => ANTAGONISTS OF GPR39 PROTEIN [patent_app_type] => utility [patent_app_number] => 17/997533 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63457 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -103 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997533 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/997533
ANTAGONISTS OF GPR39 PROTEIN Apr 29, 2021 Pending
Array ( [id] => 20401188 [patent_doc_number] => 12491147 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Personal care compositions comprising a metal piroctone complex [patent_app_type] => utility [patent_app_number] => 17/923733 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2095 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923733 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/923733
Personal care compositions comprising a metal piroctone complex Apr 28, 2021 Issued
Array ( [id] => 20271912 [patent_doc_number] => 12441681 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Synthesis of sulfonamide intermediates [patent_app_type] => utility [patent_app_number] => 17/923015 [patent_app_country] => US [patent_app_date] => 2021-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4385 [patent_no_of_claims] => 80 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923015 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/923015
Synthesis of sulfonamide intermediates Apr 27, 2021 Issued
Array ( [id] => 19777385 [patent_doc_number] => 12226405 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use [patent_app_type] => utility [patent_app_number] => 17/241981 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 61767 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17241981 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/241981
Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use Apr 26, 2021 Issued
Array ( [id] => 18468773 [patent_doc_number] => 20230203055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE [patent_app_type] => utility [patent_app_number] => 17/997328 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15287 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997328 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/997328
FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE Apr 26, 2021 Abandoned
Menu